.svg)
Living with endometriosis can bring more than just physical pain—it can affect energy levels, digestion, metabolism, and even the ability to manage weight. If you’ve been struggling with unexplained weight gain, difficulty losing weight, or changes in appetite, you may be wondering: Could GLP-1 agonists help?
Endometriosis is a complex condition that extends beyond the reproductive system. It can influence hormones, increase inflammation, and impact insulin sensitivity all of which can make weight management more challenging. Many people with endometriosis find that traditional weight loss strategies don’t work as expected, leading to frustration and confusion.
The good news is that research into GLP-1 agonists, medications originally designed for diabetes and now widely used for weight loss, is expanding. These medications not only regulate appetite but may also offer additional benefits that could be particularly relevant for those with endometriosis.
If you're looking for new options, there’s reason to be hopeful. Understanding the connection between endometriosis, metabolism, and GLP-1 medications could provide a fresh perspective on managing symptoms and improving overall well-being. Let’s explore what science says and what this could mean for you.
Potential Benefits for Pain Management and Inflammation Reduction
When it comes to pain management and reducing inflammation, there are several potential benefits associated with a range of treatments and lifestyle interventions. These can help manage chronic pain conditions and improve quality of life. Here are some key approaches:
Anti-Inflammatory Effects
GLP-1 receptor agonists (GLP-1RAs) have demonstrated significant anti-inflammatory properties, which can be particularly beneficial in managing pain and inflammation in various conditions, including those affecting the pelvic region.
- Research indicates that GLP-1RAs can mitigate oxidative stress and inflammation by regulating immune cell signalling pathways.
- GLP-1RAs have been shown to reduce the activation of nuclear factor-kappa B (NF-κB), a key regulator of inflammatory responses, thereby decreasing the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β . In the context of pelvic pain, which can be associated with conditions like endometriosis, the anti-inflammatory effects of GLP-1 agonists may help alleviate pain symptoms.
- A study found that liraglutide, a specific GLP-1RA, exhibited analgesic effects in animals by reducing inflammation in joint tissues. This suggests that similar mechanisms could be at play in pelvic inflammatory conditions, where inflammation contributes to pain.
Improved Insulin Sensitivity
Insulin resistance is often linked to chronic inflammatory conditions, including endometriosis. Elevated insulin levels can exacerbate inflammation and pain symptoms.
- GLP-1 agonists improve insulin sensitivity, which can be particularly advantageous for women suffering from insulin resistance related to obesity or metabolic syndrome. By enhancing insulin sensitivity, GLP-1RAs may help lower inflammatory markers associated with these conditions.
- A review highlighted that GLP-1RAs not only assist in glucose regulation but also possess anti-inflammatory capabilities that may contribute to their overall therapeutic effects.
- Specifically, as insulin resistance decreases, so do levels of inflammatory markers such as C-reactive protein (CRP), which is often elevated in women with endometriosis.
- This dual action improving insulin sensitivity while reducing inflammation positions GLP-1 agonists as a promising therapeutic option for managing both metabolic and inflammatory aspects of chronic pelvic pain.
Neurotransmitter Modulation
GLP-1 agonists may also influence neurotransmitter systems involved in pain perception.
- The modulation of neurotransmitters such as serotonin and norepinephrine can play a crucial role in how pain is experienced and managed. Studies have shown that GLP-1RAs can enhance the release of serotonin, a neurotransmitter known for its role in mood regulation and pain relief. By increasing serotonin levels, GLP-1 agonists may help alleviate pain symptoms associated with inflammatory conditions like endometriosis. The analgesic effects observed with liraglutide in osteoarthritis models suggest that these medications could provide similar benefits in other types of chronic pain by modulating central nervous system pathways involved in pain perception.
Interactions with Hormonal Treatments for Endometriosis
Hormonal treatments for endometriosis, such as oral contraceptives, progestins, and GnRH agonists, are used to suppress the growth of endometrial tissue outside the uterus and alleviate symptoms. When considering additional treatments for pain or inflammation, it is essential to understand potential interactions, as they may affect the efficacy or safety of hormonal therapies. Here’s a look at some potential interactions:
Combined Therapy
Combining GLP-1 agonists with hormonal treatments, such as oral contraceptives or GnRH agonists, may offer several potential benefits for managing endometriosis and related symptoms.
- GLP-1 receptor agonists like semaglutide can enhance the effectiveness of progestins, such as levonorgestrel, which are commonly used in hormonal therapies for endometriosis and endometrial cancer prevention.
- A study presented at the AACR Special Conference on Endometrial Cancer indicated that the combination of semaglutide and levonorgestrel showed promising results in preclinical models.
- The combination therapy not only reduced cell viability in endometrial cancer cell lines but also demonstrated a synergistic effect by upregulating both GLP-1 receptors and progesterone receptors. This suggests that GLP-1 agonists may enhance the therapeutic effects of progestins, potentially leading to better outcomes in managing endometriosis symptoms and reducing the risk of associated cancers.
- The anti-inflammatory properties of GLP-1 agonists may complement the effects of hormonal treatments by addressing underlying inflammation often present in endometriosis. By improving insulin sensitivity and reducing inflammation, GLP-1 agonists could help create a more favourable environment for hormonal therapies to work effectively.
Potential Drug Interactions
While the combination of GLP-1 agonists and hormonal treatments appears promising, it is essential to consider potential drug interactions. Currently, there is limited research specifically detailing interactions between GLP-1 receptor agonists and hormonal treatments for endometriosis. However, understanding the pharmacodynamics of these medications is crucial.
For instance, while GLP-1 agonists are primarily metabolised by the kidneys and have a low potential for significant drug-drug interactions, it is still important to monitor patients closely when combining therapies. Hormonal treatments can influence metabolic pathways, potentially affecting how GLP-1 agonists are processed in the body.
Consulting with a healthcare provider is vital to ensure safe and effective treatment plans. Healthcare professionals can monitor for any adverse effects or changes in efficacy when combining these therapies. For example, if a patient experiences increased gastrointestinal side effects from a GLP-1 agonist while on hormonal therapy, adjustments may be necessary to optimise comfort and therapeutic outcomes.
Current Research and Future Directions
Current research and future directions for treating pain, inflammation, and hormone-related conditions like endometriosis are advancing rapidly. Here are some promising areas:
Current State of Research on GLP-1 Agonists and Endometriosis
- Recent studies have begun to explore the potential role of GLP-1 receptor agonists in managing endometriosis, a condition characterised by the growth of endometrial-like tissue outside the uterus, leading to chronic pain and other symptoms. Current research indicates that GLP-1RAs may offer therapeutic benefits beyond their established use in obesity and type 2 diabetes management.
- A cohort study indicated that women with type 2 diabetes who received GLP-1RAs had a 27% lower risk of developing new-onset uterine fibroids compared to those treated with metformin or insulin. This suggests that GLP-1RAs may have protective effects against conditions associated with obesity and insulin resistance, which are risk factors for endometriosis and related complications .
Need for Further Studies
While these findings are promising, there is a pressing need for further research to fully understand the potential benefits and risks of GLP-1 agonists for women with endometriosis. Most current studies focus on preclinical models or specific populations, such as those with type 2 diabetes, which may not be representative of the broader population of women suffering from endometriosis.
Conclusion
Current research indicates that GLP-1RAs may enhance the effectiveness of hormonal treatments, such as progestins, while potentially reducing the side effects commonly associated with these therapies. While the findings are encouraging, it is crucial for women considering GLP-1 agonists to consult with a healthcare provider to determine if these medications are suitable for their individual needs.
Furthermore, it is essential for women with endometriosis to stay informed about the latest research and treatment options available. As studies continue to investigate the efficacy and safety of GLP-1RAs in this context, new insights may emerge that could further enhance treatment strategies and improve quality of life.
If you are struggling with weight management alongside endometriosis you can contact us at SheMed for personalised guidance. We will help you tailor a plan on GLP-1 agonists and how they might fit into your treatment. Let’s find the right approach for you!
References
- Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., Wadden, T. A., & Fineman, M. (2018). New England Journal of Medicine, 381(7), 721–732. Available at: https://pubmed.ncbi.nlm.nih.gov/30994890/
- Ahmad, S., & Ansari, I. A. (2023). The role of GLP-1 receptor agonists in the treatment of obesity and type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 16, 161–173. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9945324/
- Cunningham, M. P., Houghton, R. S., & Lewis, A. D. (2023). Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes and cardiovascular risk: A systematic review. Frontiers in Endocrinology, 14, 10230051. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10230051/
- Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., & Kaneko, S. (2017). A randomized controlled trial. The Lancet Diabetes & Endocrinology, 5(9), 743–752. Available at: https://pubmed.ncbi.nlm.nih.gov/28479155/
- Davies, M., D'Alessio, D. A., Frías, J. P., Garber, A., Gurney, K., & Lingvay, I. (2017). The Lancet, 389(10085), 1995–2005. Available at: https://pubmed.ncbi.nlm.nih.gov/29129776/
- Jørgensen, N. B., Jacobsen, S. H., & Vilsbøll, T. (2020). A systematic review and meta-analysis. Obesity Reviews, 21(4), e13019. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8419463/
- Jiang, Y., Liao, L., Yang, F., Zeng, X., & Zhang, W. (2020). A systematic review and network meta-analysis. Obesity Reviews, 21(11), e13043. Available at: https://pubmed.ncbi.nlm.nih.gov/32740121/
- Mundkur, L., & Toth, P. P. (2018). Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus. In StatPearls [Internet]. StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK547863/
- Dai, Y., Wang, C., Li, J., & Wang, X. (2021). Efficacy and safety of GLP-1 receptor agonists in patients with obesity:23(6), 1469–1478. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9045107/
- Feng, X., Li, L., & Zhang, Y. (2024). Efficacy and safety of GLP-1 receptor agonists in the treatment of obesity: Obesity Reviews, 25(1), 32–45. Available at: https://pubmed.ncbi.nlm.nih.gov/39429275/
When new medical studies are released, they can feel full of numbers and complex terms. At SheMed, our role is to help you understand what they really mean for you, your health, and your future.
Recently, Novo Nordisk released the results of the STEER study, one of the most significant pieces of research yet on GLP-1 medicines like Wegovy. And the findings show something powerful: Wegovy is not only about weight loss, it’s also about heart health.
The Big Picture: What the STEER Study Looked At
The STEER study explored how GLP-1 medicines affect heart health in people living with Overweight or Obesity and established cardiovascular disease (but without diabetes).
Researchers compared Wegovy (Semaglutide 2.4mg) with Tirzepatide (Mounjaro). They focused on the risk of serious heart problems, what doctors call “major adverse cardiovascular events” (MACE). These include:
- Heart attack
- Stroke
- Death from heart disease
What They Found
The results were striking:
- For people who stayed on treatment without big gaps, Wegovy reduced the risk of heart attack, stroke, or cardiovascular death by 57% more than Mounjaro.
- When looking at all treated people, even those with breaks in care Wegovy still showed a 29% reduction in these serious events overall.
In short, Wegovy is not only helping people lose weight, it is also showing clear cardiovascular protection, especially when used consistently.
Why This Matters for You
We’ve always known GLP-1 medicines are powerful tools for weight loss, but the STEER study highlights something even bigger: they can also protect your heart. For anyone living with Obesity and cardiovascular disease, this is game-changing.
It also reinforces an important truth - long-term commitment matters most. The people who saw the greatest benefits were those who stayed consistent with their medication. That’s why at SheMed, we design every part of our programme to keep you supported, motivated, and engaged for the long run.
The SheMed Difference: Seeing the Bigger Picture
Medication is only one part of your health journey. At SheMed, we combine Wegovy with wraparound care:
- Regular blood tests to track key markers like cholesterol, blood sugar, and liver health.
- Weekly check-ins and app reminders to help you stay on track.
- Education and content designed specifically for women, covering sleep, hormones, activity, and nutrition.
- Proactive Side effect care and support to keep you comfortable and supported as your body adjusts.
This holistic approach matters because weight loss is just one marker of progress. By running blood tests before starting the programme, at 6 months, and 12 months, we can show you the deeper changes happening inside your body, improvements in cholesterol, blood sugar, and overall metabolic health.
It means you’ll see the true value of GLP-1s, not just in how you look or feel, but in the measurable ways your health is improving and your risks are reducing.
Why Wegovy Through SheMed Makes Sense
At SheMed, we’ve worked hard to make Wegovy accessible and affordable. With static, transparent pricing across doses, our members know exactly what they’re paying. That means no hidden surprises and no price hikes as you move up through titration.
When you combine that cost benefit with the evidence from STEER that Wegovy offers not just weight loss but cardiovascular protection the case for choosing Wegovy through SheMed becomes even stronger.
You’re not just investing in weight management; you’re investing in heart health, future health, and a programme designed to keep you safe and supported every step of the way.
The Future of Health With SheMed
The STEER study is a reminder that the story of GLP-1s is still unfolding and it’s about so much more than weight loss. These medicines are changing how we think about obesity, cardiovascular health, and long-term wellbeing.
At SheMed, we’ll continue to keep you informed as new research emerges, but more importantly, we’ll keep showing you the bigger picture through your own results. With every blood test, every milestone, and every step forward, you’ll see how far you’ve come not just in weight, but in health.
Because at SheMed, you’re not just losing weight. You’re gaining health, protecting your future, and building the strongest version of you.
Wegovy has quickly become a key treatment option in obesity management, particularly for adults living with excess weight and health conditions linked to obesity.
With recent price increases for Mounjaro®, another GLP-1 medication, many patients and healthcare providers are now turning to Wegovy as a strong alternative.
Clinical research shows that Wegovy can deliver significant weight loss results, often comparable to those seen with Mounjaro, making it one of the most effective options currently available.
Recent news and clinical trial data reveal that higher doses of Wegovy specifically at 7.2 mg weekly, have led to average weight loss of around 21% in adults with obesity, with approximately one-third of participants achieving a weight loss of 25% or more over 72 weeks. This is notably greater than the 15% average weight loss seen at the standard 2.4 mg dose.
Latest Clinical Data on Higher Doses
The 2025 STEP UP phase 3b trial evaluated semaglutide at both 7.2 mg and 2.4 mg weekly doses versus placebo in people with obesity who did not have diabetes. The results indicated a clear dose-response effect:
- Mean weight loss was 21% at 7.2 mg, compared to 17.5% at 2.4 mg, and much lower with placebo.
- Specifically, 51% of those on 7.2 mg lost at least 20% of their body weight, and 33% achieved a reduction of 25% or more.
- For 2.4 mg, 35% lost 20% or more, and 17% achieved 25% or greater weight loss.
Regulatory and Safety Considerations
- Novo Nordisk has announced plans to seek regulatory approval for the higher 7.2 mg dose in the EU and other regions in late 2025.
- Safety and tolerability of the 7.2 mg weekly dose were consistent with the known profile of semaglutide, with gastrointestinal side effects remaining most common, except for a low discontinuation rate for adverse effects (about 3%).
- These findings extend the potential of Wegovy for people requiring greater degrees of weight loss, emphasising the dose-dependent effect of semaglutide GLP-1 therapy.
Comparing New findings with Mounjaro
At higher doses (7.2 mg), Wegovy has demonstrated weight loss outcomes that closely mirror those achieved with Mounjaro. Clinical data show an average 21% reduction in body weight over 72 weeks with Wegovy, with around half of patients reaching at least 20% weight loss. By comparison, Mounjaro studies report average reductions of up to 22–23% at higher doses over a similar treatment duration. While Wegovy’s 7.2 mg dose remains under regulatory review and is not yet standard practice, these findings highlight that patients considering a switch may be able to achieve results that are highly comparable to those seen with Mounjaro, offering another strong option in pharmacological obesity management.
Head-to-head style snapshot (72-week outcomes)
In conclusion, if you are considering switching from Mounjaro to Wegovy, now is an excellent opportunity. Wegovy offers a highly effective alternative for weight management with similar clinical results, and - importantly - comes at a considerably lower price, especially as Mounjaro prices are set to rise sharply in the UK from September 2025. Choosing Wegovy can help maintain your weight loss goals while making your treatment more affordable.
If you have any questions or need personalised advice about making the switch, please do not hesitate to contact the Shemed support team at support@shemed.com.
References
- ClinicalTrials.gov. (2024, December 12). A research study to see how semaglutide helps people with excess weight, lose weight (STEP UP) (NCT05646706). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT05646706
- Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Wadden, T. A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
- American Diabetes Association (ADA). (2025, June). STEP UP trial: Semaglutide 7.2 mg in adults with obesity without type 2 diabetes [Conference presentation]. ADA 85th Scientific Sessions, Chicago, IL. Retrieved from https://diabetesjournals.org/ (poster abstract ePoster 446-P).
- Novo Nordisk. (2025, June 9). Semaglutide 7.2 mg shows ~21% weight loss at 72 weeks in STEP UP trial [Press release]. Retrieved from https://www.novonordisk.com/